Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 4067-4073

  Ueno, Toshiya ^a,b   Teraoka, Naoya ^a   Takasu, Shinji ^a   Nakano, Katsuya ^a,b   Takahashi, Mami ^a   Yamamoto, Masafumi ^a   Fujii, Gen ^a   Komiya, Masami ^a   Yanaka, Akinori ^b   Wakabayashi, Keiji ^c   Mutoh, Michihiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Aberrant crypt foci; Obesity; Pioglitazone; PPAR gamma

Indexed keywords

EID: 84873649462     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.4067     Document Type: Article

References (29)

1. Bird RP (1987). Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letts, 37, 147-51.
2. Bojková B, Garajová M, Kajo K, et al. (2010). Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev, 19, 379-84.
3. Bruce WR, Wolever TM, Giacca A (2000). Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer, 37, 19-26.
4. Cowey S, Hardy RW (2006). The metabolic syndrome: A high-risk state for cancer? Am J Pathol, 169, 1505-22.
5. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9.
6. Fisher B, Costantino JP, Wickerham DL, et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 90, 1371-88.
7. Fukada T, Ohtani T, Yoshida Y, et al. (1998). STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J, 17, 6670-7.
8. Ikeda H, Taketomi S, Sugiyama Y, et al. (1990). Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung, 40, 156-62.
9. Itami A, Watanabe G, Shimada-Itami A, et al. (2001). Ligands for peroxisome proliferator-activated receptorγ inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer, 94, 370-6.
10. Iwaki M, Matsuda M, Maeda N, et al. (2003). Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655-63.
11. Kortylewski M, Heinrich PC, Mackiewicz A, et al. (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene, 18, 3742-53.
12. Le Marchand L, Wilkens LR, Kolonel LN, et al. (1997). Association of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res, 57, 4787-94.
13. Nakamura M, Yamada K (1967). Studies on a diabetic (KK) strain of the mouse. Diabetologia, 3, 212-21.
14. Niho N, Mutoh M, Takahashi M, et al. (2005). Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA, 102, 2970-4.
15. Niho N, Takahashi M, Shoji Y, et al. (2003). Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand. Cancer Sci, 94, 960-64.
16. Polyak K, Kato JY, Solomon MJ, et al. (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev, 8, 9-22.
17. Rumi MA, Sato H, Ishihara S, et al. (2002). Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor γ ligands. J Lab Clin Med, 140, 17-26.
18. Sakamoto J, Kimura H, Moriyama S, et al. (2000). Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun, 278, 704-11.
19. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. (1996). PPARalpha and PPARgammma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15, 5336-48.
20. Schoonjans K, Staels B, Auwerx J (1996). The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1302, 93-109.
21. Shah P, Mudaliar S (2010). Pioglitazone: side effect and safety profile. Expert Opin Drug Saf, 9, 347-54.
22. Shimada T, Kojima K, Yoshiura K, et al. (2002). Characteristics of the peroxisome proliferators activated receptor gamma (PPAR gamma) ligand induced apoptosis in colon cancer cells. Gut, 50, 658-64.
23. Sohda T, Momose Y, Meguro K, et al. (1990). Studies on antidiabetic agents. Synthesis of hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37-42.
24. Sporn MB, Suh N (2000). Chemoprevention of cancer. Carcinogenesis, 21, 525-30.
25. Takahashi N, Okumura T, Motomura W, et al. (1999). Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett, 455, 135-9.
26. Teraoka N, Mutoh M, Takasu S, et al. (2011). High susceptibility to azoxymethane-induced colorectal carcinogenesis in obese KK-Ay Mice. Int J Cancer, 102, 79-87.
27. Turmelle YP, Shikapwashya O, Tu S, et al. (2006). Rosiglitazone inhibits mouse liver regeneration. FASEB J, 20, 2609-11.
28. van Kruijsdijk RC, van der Wall E, Visseren FL (2009). Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev, 18, 2569-78.
29. Xiao X, Wang Y, Gong H, et al. (2009). Molecular evidence of senescence in corneal endothelial cells of senescence-accelerated mice. Mol Vis, 15, 747-61.